华仁药业(300110) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 406,703,155.73, representing a 0.86% increase compared to CNY 403,241,817.91 in the same period last year[2]. - Net profit attributable to shareholders increased by 23.65% to CNY 50,822,916.88 from CNY 41,102,886.41 year-on-year[2]. - Basic and diluted earnings per share increased by 23.56% to CNY 0.0430 from CNY 0.0348 in the same period last year[2]. - Net profit for the current period was ¥52,378,184.34, representing a 25.06% increase from ¥41,870,660.50 in the previous period[23]. - The total profit for the current period was ¥57,699,011.68, an increase of 23.4% from ¥46,751,754.94 in the previous period[23]. Cash Flow and Operating Activities - The net cash flow from operating activities rose significantly by 64.95% to CNY 110,516,832.89, up from CNY 66,998,643.75 in the previous year[2]. - Cash flow from operating activities generated a net amount of ¥110,516,832.89, an increase of 64.5% compared to ¥66,998,643.75 in the previous period[25]. - The company incurred a net cash outflow from financing activities of ¥221,122,266.65, compared to a net inflow of ¥8,761,038.55 in the previous period[26]. Assets and Liabilities - Total assets decreased by 3.36% to CNY 5,001,385,125.26 compared to CNY 5,175,510,068.92 at the end of the previous year[2]. - The company's total liabilities decreased to CNY 2,183,051,524.26 from CNY 2,399,741,641.25 at the beginning of the period[20]. - The company's cash and cash equivalents decreased to CNY 112,162,748.61 from CNY 232,043,523.45 at the beginning of the period, representing a decline of approximately 51.7%[19]. - The company reported a decrease in short-term borrowings to CNY 453,339,869.77 from CNY 624,828,010.88, a reduction of approximately 27.4%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,112[10]. - The largest shareholder, Xi'an Qujiang Tianshou Health Investment Partnership, holds 20.00% of shares, totaling 236,442,597 shares, with 118,221,298 shares pledged[10]. - The second-largest shareholder, Hongta Innovation Investment Co., Ltd., holds 7.72% of shares, totaling 91,263,000 shares[10]. - The top ten shareholders account for a significant portion of the company's equity, with the top three holding over 35% combined[10]. - The company has not disclosed any related party relationships among the top shareholders[11]. Dividends and Share Issuance - The company plans to distribute a cash dividend of RMB 0.21 per 10 shares based on a total share capital of 1,182,212,982 shares as of December 31, 2023[14]. - The company has decided to terminate the plan for a specific issuance of A-shares for 2023, pending shareholder approval[15]. Research and Development - Research and development expenses increased to ¥18,160,646.77, up 21.5% from ¥14,860,243.45 in the previous period, indicating a focus on innovation[22]. - The company and its subsidiaries passed the re-certification as high-tech enterprises during the reporting period[17]. Subsidiary Developments - The company obtained a medical device registration certificate for a negative pressure drainage device from the Shandong Provincial Drug Administration in January 2024[16]. - The company's subsidiary, Hubei Huarentongji Pharmaceutical Co., Ltd., received a cosmetics production license from the Hubei Provincial Drug Administration in February 2024[17]. - The company’s subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., received a drug supplement approval notice for Levofloxacin Injection (10ml: 0.25g) from the National Medical Products Administration in February 2024[17]. Other Financial Metrics - Total operating revenue for the current period reached ¥406,703,155.73, a slight increase of 0.36% compared to ¥403,241,817.91 in the previous period[22]. - Total operating costs decreased to ¥340,912,234.64, down 2.3% from ¥349,719,742.04 in the previous period[22]. - The company experienced a decrease in sales expenses to ¥42,875,979.11, down 22.0% from ¥55,041,516.89 in the previous period, indicating improved cost management[22].